⌕
Eton Pharmaceuticals · ETON · Nasdaq
Tenet 47 · Mixed
Compare
$63.88−0.08%At closeTenet 47 · Mixed
$63.88−0.05 (−0.08%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Eton Pharmaceuticals (ETON) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

2 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~38.3%/yr (FY21→FY25), net margin −5.8%. Worth your attention in FY25: Share count (+8.2%) and Capex step-up ($333.0K). Both visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)▲104.9%
80.0
FY21→FY25CAGR +38.3%/yr
Net income ($M)▼20.4%
−4.6
one-off year: see footnoteCAGR —
Free cash flow ($M)▲980.7%
10.2
capex stepped upCAGR —
What the receipts whisper · what a headline number hides
Share count
+8.2%

25.2mn → 27.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$333.0K

▲1181% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)79950.0Revenue−37210.0COGS42740.0Gross profit−7765.0R&D−35819.0SG&A−844.0Op income−3757.0Tax & other−4601.0Net income

-6¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
705335180%sector median net margin ~4%FY21FY25

Net margin -5.8% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
141,061.079,950.039,011.031,642.021,251.021,832.0▲104.9%+38.3%
Cost of revenue
43,512.037,210.015,600.010,581.06,933.02,827.0▲138.5%+90.5%
Gross profit
97,549.042,740.023,411.021,061.014,318.0—A▲82.6%+44.0%
Research & development
9,919.07,765.03,255.03,322.03,996.06,235.0▲138.6%+5.6%
Selling, general & admin
46,945.035,819.022,753.018,931.018,582.014,265.0▲57.4%+25.9%
Total operating expenses
56,864.043,584.026,008.022,253.022,578.020,500.0▲67.6%+20.8%
Operating incomefeeds ROC rank
40,685.0−844.0−2,597.0−1,192.0−8,260.0−1,495.0▲67.5%—
Other income, net
−3,622.0−3,714.0−1,211.0503.0−761.0−460.0——
Pretax income
37,063.0−4,558.0−3,808.0−689.0−9,021.0−1,955.0▼19.7%—
Income tax
−12,801.043.015.0247.00.00.0▲186.7%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
49,864.0−4,601.0−3,823.0−936.0−9,021.0−1,955.0▼20.4%—
Per share
Diluted shares (mn)
33.2627.2826.8225.6925.4625.21▲1.7%+2.0%
Margins
Gross margin56th pct in Healthcare
69.2%53.5%60.0%66.6%67.4%—A▼6.6pp−13.9pp
Operating margin
28.8%−1.1%−6.7%−3.8%−38.9%−6.8%▲5.6pp+5.8pp
Net margin97th pct in Healthcare
35.3%−5.8%−9.8%−3.0%−42.4%−9.0%▲4.0pp+3.2pp
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was −36% vs a −0% norm for this window, likely a one-time item; see the filing.A Withheld: this year's gross margin is not on the same cost basis as the earlier years.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Eton Pharmaceuticals' revenue last fiscal year?

Eton Pharmaceuticals reported revenue of $80.0M in fiscal 2025, up 104.9% from fiscal 2024.

What was Eton Pharmaceuticals' net income?

Eton Pharmaceuticals reported net income of −$4.6M in fiscal 2025, a net margin of −5.8%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.